Effect of Curodont Repair in Patients With Early Approximal Carious Lesions
Launched by CREDENTIS AG · Apr 17, 2014
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
All study participants must have two early approximal carious lesions in need of a treatment but not of an invasive treatment (split-mouth design). One lesion will be treated with Curodont Repair and the other will not undergo a treatment as control. Study duration is 12 months. For assessment x-ray pictures are used.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Two approximal carious lesions on different teeth with at least one tooth in between
- • Both study lesions must not require an invasive treatment
- • Size and form of the lesions: the lesions must be fully visible and assessable on radiographs
- * The two carious lesions must fall into classes:
- • D1 (outer half of enamel) D2 (inner half of enamel) D3 (outer part of dentine) but only if very little dentine is involved (enamel-dentine junction)
- • Able and willing to observe good oral hygiene throughout the study
- • Age ≥ 18 years and ≤ 65 years
- • Willing and able to attend the on-study visits
- • Willing and able to understand all study-related procedures
- • Written informed consent before participation in the study
- Exclusion Criteria:
- • The two study test lesions are located on adjacent teeth
- • Fluoride varnish application \< 3 months prior to study treatment
- • Tooth with numerous carious lesions
- • Evidence of tooth erosion
- • History of head and neck illnesses (e.g. head/neck cancer)
- • Any pathology or concomitant medication affecting salivary flow or dry mouth
- • Any metabolic disorders affecting bone turnover
- • Patient suffers from diabetes
- • Concurrent participation in another clinical trial
- • Women who are breast-feeding, pregnant or who plan a pregnancy during the study
- • Women of childbearing potential who declare being unwilling or unable to practice contraception such as hormonal contraceptives, sexual abstinence or intercourse with a vasectomised partner
About Credentis Ag
Credentis AG is a leading Swiss biotechnology company specializing in the development of innovative dental therapies and products. Focused on enhancing oral health, Credentis leverages cutting-edge technologies to create solutions that address unmet needs in dental care, including minimally invasive treatments and regenerative approaches. With a commitment to research and development, the company aims to improve patient outcomes and quality of life through its clinically validated products, demonstrating a strong dedication to advancing the field of dentistry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Patients applied
Trial Officials
Rolf Heimlinger, Dr. med. dent.
Principal Investigator
zumstein dental clinic ag
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials